Sign In
Buy IPSEY
$46.50
+1.11 (+2.45%)
At Close: Jun 23, 2026
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
04:00am, Thursday, 15'th Feb 2024
Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements
US FDA approves Ipsen's rare bone disorder drug
03:42pm, Wednesday, 16'th Aug 2023
The U.S. Food and Drug Administration on Wednesday approved French drugmaker Ipsen's bone disorder drug, making it the first treatment available to patients with the rare condition that causes abnorma
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicate
Ipsen S.A. publishes its 2023 Half-Year Financial Report
12:06pm, Thursday, 27'th Jul 2023
Ipsen S.A. publishes its 2023 Half-Year Financial Report Attachment 2023 Half-year Financial Report
Ipsen S.A. (IPSEY) Q4 2022 Earnings Call Transcript
07:15pm, Thursday, 09'th Feb 2023
Ipsen S.A. (OTCPK:IPSEY) Q4 2022 Results Conference Call February 9, 2023 7:45 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - CFO Howard Mayer - Head, Research and Development Conf
Ipsen S.A.'s (IPSEY) CEO David Loew on Q2 2022 Results - Earnings Call Transcript
06:07am, Saturday, 30'th Jul 2022
Ipsen S.A. (OTCPK:IPSEY) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Chief Financial Officer Howard M
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
01:00am, Monday, 27'th Jun 2022
PARIS & CAMBRIDGE, MASS.--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today
Ipsen S.A. (IPSEY) CEO David Loew on Q4 2021 Results - Earnings Call Transcript
03:34pm, Friday, 11'th Feb 2022
Ipsen S.A. (IPSEY) CEO David Loew on Q4 2021 Results - Earnings Call Transcript
Ipsen S.A. (IPSEY) CEO Francesco Caio on Q2 2021 Results - Earnings Call Transcript
12:39am, Monday, 02'nd Aug 2021
Ipsen S.A. (IPSEY) CEO Francesco Caio on Q2 2021 Results - Earnings Call Transcript
Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui que de nouvelles données d’essais cliniques et en vie réelle concernant di
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the
